LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Carsten-Henning OhlmannMichelle JäschkePeter JaehnigSusanne KregeJürgen GschwendHeidrun RexerKerstin JunkerRoger ZillmannChristoph RüsselEva HellmisHenrik SuttmannMartin JanssenJan MarinAndreas HübnerMichael MathersJochen GleißnerMichael SchefflerSusan FeyerabendJens TelleJörg KlierMichael StöcklePublished in: Prostate cancer and prostatic diseases (2022)
AA + P treatment without ADT may be effective in mCRPC patients and ADT may not be necessary in patients receiving AA + P.
Keyphrases
- phase ii
- open label
- clinical trial
- phase iii
- double blind
- placebo controlled
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- study protocol
- peritoneal dialysis
- stem cells
- squamous cell carcinoma
- locally advanced
- minimally invasive
- combination therapy
- patient reported
- chemotherapy induced